EPS for Intec Pharma Ltd. (NTEC) Expected At $-0.19

March 14, 2018 - By Louis Casey

 EPS for Intec Pharma Ltd. (NTEC) Expected At $ 0.19

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.19 EPS on April, 6.They anticipate $0.13 EPS change or 40.63 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Intec Pharma Ltd.’s analysts see -52.50 % EPS growth. The stock increased 0.77% or $0.05 during the last trading session, reaching $6.55. About 129,122 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 51.00% since March 14, 2017 and is uptrending. It has outperformed by 34.30% the S&P500.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Coverage

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, September 21 by Oppenheimer. The stock has “Buy” rating by Roth Capital on Thursday, August 10. Oppenheimer initiated Intec Pharma Ltd. (NASDAQ:NTEC) rating on Thursday, June 22. Oppenheimer has “Buy” rating and $1000 target. The firm has “Buy” rating by Maxim Group given on Wednesday, September 16. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Friday, September 11 by TH Capital. Roth Capital maintained Intec Pharma Ltd. (NASDAQ:NTEC) on Thursday, August 3 with “Buy” rating. Oppenheimer maintained it with “Buy” rating and $15.0 target in Thursday, November 16 report. The company was maintained on Monday, July 24 by Roth Capital. The company was initiated on Friday, September 11 by Roth Capital.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $157.65 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More notable recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: Prnewswire.com which released: “Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and …” on March 09, 2018, also Prnewswire.com with their article: “Intec Pharma, Ltd. Announces Changes to its Board of Directors” published on November 01, 2017, Prnewswire.com published: “Intec Pharma Granted Patent in Canada for Accordion Pillâ„¢ Carbidopa / Levodopa” on January 03, 2018. More interesting news about Intec Pharma Ltd. (NASDAQ:NTEC) were released by: Seekingalpha.com and their article: “Intec Pharma: Buy The Dip” published on October 15, 2017 as well as Prnewswire.com‘s news article titled: “Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa …” with publication date: March 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: